Markets move fast. You should move faster. Be the first to know when deals break, stocks move, or biotech headlines hit. Sign up to get breaking news alerts the moment they happen.
Chinese EV sales stumbled in February 2026 due to the Spring Festival holiday, with major players like BYD and XPeng seeing sharp drops. This pressures Tesla in its key China market, raising the importance of its pivot to AI, robo-taxis, and humanoid robots for future growth.
Berkshire Hathaway’s operating profit fell 29% in Q4 2025—Warren Buffett’s final quarter as CEO—driven by weak insurance results. Greg Abel will take over. No share repurchases were made.
FDA approves Ascendis Pharma's Yuviwel, the first once-weekly injection to boost growth in children 2+ with achondroplasia. Launch expected Q2 2026.
Aardvark Therapeutics voluntarily pauses Phase 3 HERO trial of ARD-101 for Prader-Willi hyperphagia after reversible cardiac signals in high-dose study. Updates expected Q2 2026.
EchoStar jumps on fresh reports of SpaceX planning a massive confidential IPO filing as soon as March 2026, targeting a huge $1.75+ trillion valuation.
Data center and AI-related stocks like CoreWeave plunged sharply as rising credit risks and heavy spending fears spark a sell-off in speculative tech trades. Investors are pushing back against big capital expenses.
